Orphan, The

Thrombotargets Corp. is proud to announce its orphan drug designation for the second TT-103MH for the treatment of bleeding episodes, now in patients with Von Willebrand.

TT-103MH was granted a last February orphan drug status for treatment of bleeding in hemophiliacs. Now Thrombotargets Company recombinant human TT-103MH, has been granted by the Food and Drug Administration (FDA) orphan drug designation for the drug in the treatment of patients with von Willebrand "We are very proud of this drug designation orphan drug. This is the second time the FDA granted a TT-103MH orphan drug in less than a year and we look forward to a bright future for TT-103MH. To increase our market potential, we will continue to perform new applications for orphan drug designation for coagulation disorders were additional TT-103MH showed physical activity and we believe that TT-103MH become a blockbuster in the near future because of this strategy "said Dr. Pedrea±o, president and CEO.

About Thrombotargets Group
Thrombotargets ( www.thrombotargets.com ) is a privately held biotechnology company specializing in the discovery and development of innovative drugs in hemostasis, thrombosis and atherosclerosis. The company has a number of potential new drugs in development objectives and its internal proprietary and innovative platforms uHTS programs are used for internal drug discovery and for the licensing and partnering for new projects research.